Search

everythinglearnresearchcommunity

for

Search:↓

ERG increases SOX9, promoting prostate cancer growth and invasion.

PSA is best for detecting prostate cancer recurrence and evaluating treatment response.

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Overexpressing SSAT enzyme reduces prostate tumor growth in mice.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Selenium and vitamin E supplements have mixed effects on prostate cancer risk and may not be beneficial for everyone.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

The guidelines aim to find treatable prostate cancer early while avoiding unnecessary tests and treatments.

Prostate cells have proteins that bind to specific hormones, which can increase protein production when activated by these hormones.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.

Large prostate links to more hair loss, but age of onset doesn't affect it.

Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.